Literature DB >> 12586978

Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.

Taneli Puumalainen1, Ron Dagan, Tomi Wuorimaa, Rose Zeta-Capeding, Marilla Lucero, Jukka Ollgren, Helena Käyhty, Hanna Nohynek.   

Abstract

BACKGROUND: Antibody responses to pneumococcal conjugate vaccines may vary when administered in different populations or epidemiologic settings. Understanding the causes and significance of this variation could help to determine the number of doses and timing required for protection against pneumococcal diseases in each country.
METHODS: This report compares antibody responses to aluminum-adjuvanted and nonadjuvanted mixed carrier 11-valent diphtheria- or tetanus-conjugated pneumococcal vaccine (11-PncTD) formulations when given at 6, 10 and 14 weeks and 9 months of age to Filipino infants (n = 51) and at 2, 4, 6 and 12 months of age to Finnish (n = 127) and Israeli (n = 124) infants. The study populations differ in their natural exposure to pneumococcus and risk factors for pneumococcal carriage and disease.
RESULTS: Filipino and Israeli infants had slightly but significantly higher prevaccination geometric mean concentration (GMC) of antibodies than did the Finnish infants. After three doses of aluminum-adjuvanted 11-PncTD vaccine, the Filipino infants had 1.8 to 6.7 and 1.5 to 5.0 times higher GMC than the Finnish and Israeli infants, respectively, against pneumococcal serotypes conjugated to tetanus protein. The GMC of serotypes conjugated to diphtheria toxoid was 1.3 to 3.0 and 0.7 to 2.0 times the GMC in Finnish and Israeli infants, respectively. The nonadjuvanted vaccine formulation induced generally lower GMCs.
CONCLUSIONS: The antibody responses to the tetanus-conjugated polysaccharides were considerably higher in the Filipino than in the Finnish or Israeli infants. This may be a result of several factors including the priming effect of tetanus toxoid given to pregnant women, early pneumococcal nasopharyngeal acquisition and genetic differences among populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586978     DOI: 10.1097/01.inf.0000050459.74134.d5

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

Review 1.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 2.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

5.  Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.

Authors:  F M Russell; A Balloch; M L K Tang; J R Carapetis; P Licciardi; J Nelson; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; G B Byrnes; Y B Cheung; E K Mulholland
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

6.  Evaluation of antibody response to the heptavalent pneumococcal conjugate vaccine in pediatric chronic kidney disease.

Authors:  Simone Vieira; Evandro Roberto Baldacci; Magda Carneiro-Sampaio; Ulysses Doria Filho; Vera Hermina Koch
Journal:  Pediatr Nephrol       Date:  2008-09-17       Impact factor: 3.714

Review 7.  Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics.

Authors:  Giorgio Sirugo; Branwen J Hennig; Adebowale A Adeyemo; Alice Matimba; Melanie J Newport; Muntaser E Ibrahim; Kelli K Ryckman; Alessandra Tacconelli; Renato Mariani-Costantini; Giuseppe Novelli; Himla Soodyall; Charles N Rotimi; Raj S Ramesar; Sarah A Tishkoff; Scott M Williams
Journal:  Hum Genet       Date:  2008-05-30       Impact factor: 4.132

8.  Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.

Authors:  Alassane Dicko; Olumuyiwa O Odusanya; Abdoulbaki I Diallo; Gaoussou Santara; Amadou Barry; Amagana Dolo; Aminata Diallo; Yetunde A Kuyinu; Omolara A Kehinde; Nancy François; Dorota Borys; Juan P Yarzabal; Marta Moreira; Lode Schuerman
Journal:  BMC Public Health       Date:  2011-11-23       Impact factor: 3.295

9.  A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.

Authors:  Fong Seng Lim; Mia Tuang Koh; Kah Kee Tan; Poh Chong Chan; Chia Yin Chong; Yeo Wee Shung Yehudi; Yee Leong Teoh; Fakrudeen Shafi; Marjan Hezareh; Kristien Swinnen; Dorota Borys
Journal:  BMC Infect Dis       Date:  2014-10-02       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.